Next Article in Journal
Rapid and Visual Detection of Volatile Amines Based on Their Gas–Solid Reaction with Tetrachloro-p-Benzoquinone
Next Article in Special Issue
Synthesis of Rhodamine-Conjugated Lupane Type Triterpenes of Enhanced Cytotoxicity
Previous Article in Journal
Microscopic Understanding of Interfacial Performance and Antifoaming Mechanism of REP Type Block Polyether Nonionic Surfactants
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Bond Formation at C8 in the Nucleoside and Nucleotide Purine Scaffold: An Informative Selection

by
Kjell Undheim
Department of Chemistry, University of Oslo, 0315 Oslo, Norway
Molecules 2024, 29(8), 1815; https://doi.org/10.3390/molecules29081815
Submission received: 6 March 2024 / Revised: 22 March 2024 / Accepted: 1 April 2024 / Published: 17 April 2024

Abstract

:
This paper presents methods for the introduction and exchange of substituents in a nucleobase and its nucleosides and nucleotides with emphasis on the C8-position in the purine skeleton. The nucleobase is open for electrophilic and nucleophilic chemistry. The nucleophilic chemistry consists mainly of displacement reactions when the C8-substituent is a good leaving group such as a halogen atom. The heteroatom in amines, sulfides, or oxides is a good nucleophile. Halides are good reaction partners. Metal-promoted cross-coupling reactions are important for carbylations. Direct oxidative metalation reactions using sterically hindered metal amides offer chemo- and regio-selectivity besides functional tolerance and simplicity. The carbon site is highly nucleophilic after metalation and adds electrophiles resulting in chemical bond formation. Conditions for metal-assisted reactions are described for nucleobases and their glycosides.

Graphical Abstract

1. Introduction

Recent years have seen great changes in synthetic heterocyclic chemistry powered by the application of organometallic chemistry. Attention is centered on syntheses, new methodologies for chemical bond formation, chemoselectivity, stereoselectivity, regioselectivity, functional activations, and protection. Information and reviews in these areas will be helpful for work with complex organic molecules. Reference is made to medicinal chemistry and the search for new organic molecules for potential application in medicine.
The purine nucleobases adenine and guanine are incorporated in essential molecular biological systems. Modifications of their chemical structure are widely used in search for products that are potentially beneficial for medical applications including antivirals [1,2]. In this report, the focus is on the preparation and properties of molecules with a C8-substituent in the purine scaffold and selected bioactivities associated with the structural modifications in the heterocycle as well as in corresponding nucleosides and nucleotides. Substitutions in the pyrimidine moiety in purines follow the normal course for electron deficient π-systems. The regiochemistry, however, may be affected or controlled by annulations and functional substituents. The chemistry in the C8-position in the purine scaffold is special in that it is active in both electrophilic and nucleophilic substitution reactions. The rich chemistry in the fused purine structure associated with the electrophilic or π-electron deficient pyrimidine C2- and C4-positions falls outside the scope of this presentation. In the annulated imidazo ring, chemistry is mainly concentrated in the imidazole C2-position that is numbered as the C8-position in the purine skeleton. Oxidative metalations and metal promoted cross-coupling reactions are important methodologies for the new bond-forming reactions at the C8-position in the purine scaffold [3,4].

2. Carbylations

2.1. Alkylations

The chemistry presented in this report starts with the introduction of simple alkyl groups. The C8-hydrogen atom in purines and purine nucleosides is relatively acidic and undergoes hydrogen exchange when treated with a strong base such as LDA. The sugar hydroxyl groups of adenosine are protected as silyl ethers prior to metalation, structure 1. LDA is used for the lithiation of the silyl-protected adenosine in THF (Scheme 1). Treatment of the metalated species with MeI at low temperature affords the C8-methyl product 2 that is deprotected by TBAF to afford the C8-methyl derivative 3 [5].
Stannanes are effective alkylating agents in Pd-catalyzed cross-couplings. C8-Methylation and -ethylation of adenosine analogues with tetraalkyltin reagents and Pd(0)-catalysis starts from C8-Br-adenosine to afford the corresponding cross-alkylated products 6 (Scheme 2) [6]. Silyl protection of substrates 4 affords persilylated ethers on heating with hexamethyldisilazane in dioxane to deliver intermediates 5. Trans-coupling of the silyl ether intermediates with tetraalkyltin in N-methylpyrrolidinone (NMP) in the presence of Pd(PPh3)4 affords the C8-methyl and -ethyl derivatives in high yields. The protection groups are removed by ammonium chloride in methanol.
Aluminum organyls are useful reagents for alkylation reactions promoted by Pd-catalysis. Cross-coupling of tris(tetrabutyldimethylsilyl) (TBDMS) protected C8-bromoadenosine 4a and trimethylaluminum as methyl donors under the influence of Pd-catalysis provides the C8-methyladenosine 7 in high yields (Scheme 3) [7]. Deprotection is effected by tetrabutylammonium fluoride (TBAF). C8-methyladenosine is obtained in high yield from silyl-protected (Rp)-C8-bromo-cGMPS (8) and AlMe3 using PdCl2 and Ph3P for catalytic promotion in THF. Closely related C8-alkyl derivatives in the guanosine series are available by the same procedure from C8-Br-guanosine (8) as well as 2′-deoxyanalogues.

2.2. Alkenylations

For the preparation of C8-vinyl adenosine (12) by palladium-catalyzed cross-coupling reactions the silyl protected C8-iodo nucleoside 10 is reacted with tributylvinylstannane in DMF (Scheme 4). The yield of product 11 is close to quantitative. Deprotection by ammonium fluoride in methanol affords 12 in 50% yield [8]. Structural modification at the C8-position in purine nucleosides may affect preferential conformations of the glycosidic bond. The ethenyl group in the C8-position in adenosine induces opposite conformation preference of the glycosidic bond as compared to the natural nucleosides. A vinyl group at C8 of adenosine provides nucleosides with cytostatic activity against several murine and/or human tumor cell lines [8].
The hydroxyl functions in the 8-iodo substrate 13 is protected as TBDMS derivatives for the intended synthesis of C8-vinyladenosine 5′-diphosphate (19) and 5′-triphosphate 20 (Scheme 5) [9]. Trans-coupling delivers the vinyl derivative 14. Removal of the tert-butyl protection was to be by TFA:H2O (95:5) but the acidic conditions led to extensive depurination. In an alternative approach, the fully protected substrate 13 is desilylated and the product is acetylated to afford the diacetate 16. Trans-coupling with tributylvinyl stannane as a reactant delivers the product 17. The acetyl protection of the 2′,3′-hydroxyl functions suppresses the tendency for depurination of the coupling product 17 during the acid treatment of the phosphorotriester to afford 18. The acetyl groups are retained as protecting groups in the subsequent common steps for phosphate formations. The vinyl group is unaffected by ammonia treatment. Condensation of phosphate or pyrophosphate anion with the phosphoroimidazolate intermediate in the phosphate preparations delivers the protected phosphate. Ester protection is removed on treatment with ammonia. The sodium salts of the di- and triphosphates of C8-vinyladenosine 19 and 20 are isolated by ion exchange chromatography in respective 9 and 4% overall yield. The exocyclic double bond in C8-vinyladenosine and C8-vinyl purine is electron deficient. The addition of nucleophiles is therefore likely to occur as in a Vilsmeyer addition. The C8-vinyladenosine products show significant anti-tumoral and anti-viral activity.

2.3. Alkynylation

Sonogashira alkynylation of silyl-protected C8-iodoadenosine (10) readily yields the C8-alkynyl product 21 (Scheme 6) [8]. A subsequent TFA-driven deprotection affords C8-acetylenic adenosine 22 in 85% yield. In the guanosine series, the unprotected bromide 23 reacts equally well to provide products 24, demonstrating that protection of the sugar hydroxyl substituents is not required. The products are π-conjugated linear acetylenes attached to guanosine and adenosine, covalently modified fluorescent nucleosides are valuable probes of DNA and RNA helix-to-coil transitions, DNA and RNA chain elongation, protein-nucleic acid complexes, and cellular signal transduction pathways. Sonogashira alkynylation of unprotected C8-brominated adenosines and guanosines (23) provides products 24 with fluorescent properties.
In the transformation of C8-halopurines 25 by alkynylation acetyl protection of the sugar hydroxyl groups in the substrate is used [10]. The products are the triacetates 26 (Scheme 7). The reactions of substrate 4a, however, show that the protection of the sugar hydroxyl substituents is not required for the trans-coupling to afford the alkyne 27. The alkynes are convenient substrates for further conversions into alkenes by catalytic reduction processes as in the preparation of the C8-alkene 28 (Scheme 7).
Lithiation of C6-chloro-C9-(tetrahydro-2H-pyran-2-yl)-9H-purine 29 using LiTHP (Scheme 8) provides access to metalation in the vacant 2- and 8-positions [11]. A subsequent electrophilic addition to the metalated species introduces 2- and 8-substituents. Iodides by iodine and bromides by 1,3.dibromo-3,5-dimethyl-hydantoin. The halogenation and carbon-carbon trans-coupling reactions are illustrated by structures 30 and 31.
C8-Bromo-2′-deoxyadenosine 32 reacts in a similar manner to afford the alkyne 33 (Scheme 9) [12]. Additional syntheses of antiviral C8-alkynyl-, C8-alkenyl- and C8-alkyl-2′-deoxyadenosine analogues by cross-coupling of C8-bromo- 2′-deoxyadenosine substrates are illustrated by the preparation of the alkenes 35 and the fully hydrogenated alkanes 36.
Further attachments of alkynyl chains to the C8-position in C8-bromoadenosine 4a is affected by Pd-catalyzed cross-coupling in dry DMF containing NEt3 (Scheme 10) [13]. (Ph3P)2PdCl2 and CuI are the catalytic promotors for the formation of the C8-alkynylated products 37 (Scheme 10). Reaction of a phenylhydroxypropyne substrate affords the phenylketopropenyl product 38 by a rearrangement in the side-chain. NMR data show that the product (E)-8-(3-oxo-3-phenyl-1-propen-1-yl)-β-D-ribofuranosyl)adenine 38 prefers a syn conformation. The C8-alkynyl products are selective antagonists of the A3 adenosine receptor.

2.4. Arylation and Heteroarylation

Aryl and heteroaryl functions can be substituted into the C8-position in purines by organometallic-promoted cross-coupling reactions [14]. The Pd/Cu-mediated direct arylation of 2′-deoxyadenosine (39) with aryl iodides in Scheme 11 affords C8-arylated 2′-deoxyadenosine (40) derivatives. The combination of cesium carbonate with a secondary amine such as piperidine generates in situ a reagent complex [(CH2)5NH]2Pd(OAc)2 that promotes the trans-coupling. Cu(I) is an efficient cocatalyst for the reaction leading to C8-arylated-2′-deoxyadenosines. Results from conformational preferences of the C8-aryl-2′-deoxyadenosine products in solution are presented. The instability of the glycosyl bond at higher temperatures (>100 °C), is a significant problem for this type of chemistry.
Suzuki conditions in aqueous solutions with unprotected C8-bromo-GMP or C8-bromo-GTP substrate and arylboronic acid afford C8-arylated guanosine mono- and triphosphates using a catalyst system composed of Pd(OAc)2 and tris(3-sulfonatophenyl)phosphine (TPPTS) (Scheme 12) [15,16]. All three purine nucleotides 42 are formed by trans-coupling with phenylboronic acids under these conditions. The nucleoside products are generally isolated from aqueous media in good to excellent yields. Cosolvents such as MeCN or dimethoxyethane (DME) in water with the catalyst system Pd(OAc)2 and TPPTS as a water-soluble phosphine ligand.
Water-soluble phosphines TPPTS and TXPTS in combination with Pd(OAc)2 are efficient and general catalysts for the synthesis of C8-arylpurine nucleosides (Scheme 13) [17]. The reaction is achieved in a one-step Suzuki arylation of unprotected halonucleosides using water-soluble Pd-catalysts derived from TPPTS and Pd(OAc)2. Tri-(4,6-dimethyl-3-sulfonatophenyl)phosphine (TXPTS) reacts in a similar manner in a Suzuki coupling with the C8-bromide. C8-Bromo-2′-deoxyguanosine (8-ArdG) (43) is coupled with arylboronic acids to give C8-aryl-2′-deoxyguanosine (8-ArdG) 44 in high yield in water:MeCN (2:1). The TPPTS ligand is superior to water-soluble alkylphosphines for this coupling. The reaction can be carried out in water without an organic cosolvent.
A series of C8-alkynyl and -alkenyl nucleosides have been synthesized in a search for C8-(p-CF3-cinnamyl)-modified purine nucleosides for use as fluorescent probes (Scheme 14) [18]. Natural nucleotides are not useful as fluorescent probes because of their low quantum yields. Extrinsic fluorescent dyes coupled to nucleobases in oligonucleotides are investigated as potential agents for the detection of RNA and DNA. Adenosine and guanosine fluorescent analogues conjugated at the C8-position with aryl/heteroaryl moieties either directly, or via alkenyl or alkynyl linkers (Scheme 14). Small structural modifications at the nucleobase are used to reduce or avoid their influence on the base-pairing. The aromatic (heteroaromatic) moieties are conjugated to the purine via an alkenyl or alkynyl linker. These molecules are generally composed of three moieties: (i) an electron donor such as an electron-rich aryl group, (ii) an electron acceptor such as an electron-poor aryl moiety, (iii) an electron-rich linker that is a double or triple bond. The fluorescent products are designed as push-pull probes to enhance the fluorescent properties of purine nucleosides. Suzuki coupling provides products 45 and Sonagashira coupling affords products 46. Single-step reactions leading to the desired nucleoside products are without protecting groups. Synthetic target molecules 47 and 48 are available in the guanosine series.
Replacement of one of the oxygen atoms pendant from the phosphorus atom in adenosine-3′,5′-cyclic phosphoric acid (cAMP) with another atom creates new chirality at the phosphorus atom. In (RP)-adenosine-3′,5′-cyclic phosphorothioic acid (cAMPS), one of the oxygen atoms (52) has been replaced by a sulfur. The thiylated epimers (cAMPS) can be separated. The structurally stable cAMPS stereoisomers differ in their biological activities. A stereocontrolled preparation of C8-substituted (RP)-adenosine-3′,5′-cyclic phosphorothioic acids is available (Scheme 15) [1]. Configurational selectivity in the reaction at the phosphorus atom is a main challenge in synthesis. The synthesis, as illustrated in Scheme 15, proceeds via a stereospecific amidation using bulky silyl protection of the sugar hydroxyl group. Treatment of the substrate with (COCl)2 in DMF/ CH2Cl2 at −20 °C followed by the addition of a primary amine to the intermediate acid chloride species delivers the amidate (Sp)-50 in a regiospesic manner with the desired (S)-configuration at the phosohorus atom. This suggests structural rigidity and high conformational preference in the substrate. Introduction of the C8-aryl group to afford the trans-coupled product (Sp)-51, has the corresponding bromide 50 as substrate. The amidate (Sp)-51 is subsequently deprotonated by metalation using a strong base such as tBuOK or BuLi in THF. This operation requires an amidate derived from a primary amine. CS2 is added and forms an adduct with the negatively charged amidate nitrogen whereby a sulfur atom becomes a nucleophile. A subsequent cyclization reaction occurs where a sulfur atom adds to the phosphorus atom with a concurrent cleavage of the P-N bond. This process generates the phosphorothioic acid products (Rp)-52 in a stereocontrolled manner with retention of the true configuration at the phosphorus atom. There is, however, an apparent change in the configuration because of the nomenclature priority rules.
Cross-coupling of the bromopurine 49 with 4-substituted bromobenzene after stannylation is promoted by Pd-catalysis to afford the 4-fluorophenyl product 51 [19]. The product 51 is an amidate from a primary amine. The silyl-protected amidates are, in many cases, sufficiently soluble in appropriate common organic solvents for reactions in non-aquous media. The thiylated product is desilylated to provide the thioate 52.
The low solubility of nucleosides and nucleotides in organic solvents may be modified by masking procedures. The reaction sequence from 53 to 55 demonstrates ready couplings with both electrophilic and nucleophilic hetarenes (Scheme 16). Clean desilylation occurs with ammonium fluoride in DMF solution. The addition of n-tributylamine to the acids affords corresponding n-tributylammonium salts that are soluble in polar organic solvents that allow purification by flash chromatography [1].
cAMP and cGMP possess low penetration power of intact cellular membranes due to the polar ionic interaction of the cyclic phosphate moiety. Nucleotide analogues with hydrophobic aryl or heteroaryl substituents in the C8-position in cAMP as well as in cAMPS analogues can partly or fully overcome this problem and are used to elucidate their functional roles. A synthesis of amidine analogues 58 starts with the arylation of C8-bromo-2′,5′-dideoxy guanosine (56) by a Suzuki coupling with arylboronic acids in aqueous methanol containing sodium carbonate and Pd(OAc)2 to afford C8-arylguanines 57 (Scheme 17) [20]. The coupling proceeds in dilute TPPTS. The C8-arylpurines are useful substrates for the construction of synthetic oligonucleotides. It is suggested that dialkylformamidine protection of exocyclic amino groups reduces the lability of the glycosidic bond and renders the respective nucleosides less prone to decomposition. Reaction of N,N-dimethylformamidine dimethyl acetal in methanol affords N,N-dimethylformamidine 58. The reaction is essentially quantitative. In subsequent reaction steps, phosphoramidites are substrates for the synthesis of C8-arylpurine modified oligonucleotides.

2.5. C8-α-Functionalized C1-Substituents

Functionalized C1-substituents in the C8-position can be introduced by one-step synthetic methodology (Scheme 18) [21]. C8,N6-diformyl derivative 61 is the major product and the C8-formyl 62 is the minor product in a reaction that starts with lithiation of nucleoside 59 using LDA in THF at −78 °C followed by treatment with methyl formate. The C8-formyl derivatives 62 are obtained in high yield when the formylating agent is DMF. The method is equally applicable to reactions of the more labile 3,5-di-TMDMSO protected 2′-deoxyadenosine 59 and the 2′-deoxy analogue 60 to afford C8-formyl products 63 and 64 in high yields.
Zincation of methoxymethyl- (MOM)-protected C6-chloro-C2-trimethylsilylpurine is regioselective for the vacant 2-position using TMPZnCl·LiCl for the metalation (Scheme 19). The metalated species 66 undergoes Pd-catalyzed trans-acylation to afford the furyl ketone 67 [22].
Scheme 20 shows the preparation of adenosines carrying an oxo group or a hydroxyl group at the α-carbon in the C8-substituent [23]. The starting material is the cross-coupled C8-(α-ethoxyethenyl)adenosine 68. Potassium carbonate in methanol removes the ester protection and mild acid conditions cleave the vinyl ether function with the formation of the ketone 70. The latter can be reduced by sodium borohydride to the corresponding α-hydroxy product as an epimeric alcohol mixture at the C8-α-carbon (71).
C8-Cyanoadenosine is accessible from the corresponding iodide and zinc cyanide by Pd-promoted cross-coupling (Scheme 21) [24]. Simple nucleophilic displacement of the bromine substituent using sodium cyanide is less satisfactory. With 1,1′-bis-(diphenylphosphino)ferrocene (DPPF) as phosphorus ligand for the Pd-catalyst and zinc cyanide as reactant the coupling with fully TBDMS-protected C8-bromoadenosine proceeds satisfactorily. The yield of the C8-cyanide 72 is 68%. The TBDMS groups are removed by TBAF in THF at ambient temperature. Desilylation requires low temperatures to reduce decomposition reactions. Desilylation at 0 °C with concurrent removal of the solvent at the same temperature provides the C8-cyanoadenosine 73 in high yield.

3. Organometalations

Regioselective metalation in multifunctional heteroarenes provides an important methodology for structural modifications. Organometalation reactions commonly involve metalations by halogen or equivalents at some stage to metal exchange for new carbon-bond formation. Reference is made to the trans-coupling reactions discussed (vide supra). In the subsequent part, examples of important oxidative metalation by hydrogen-to-metal exchange are illustrated (vide infra). The reactivity of a metal-carbon bond is dependent on its polarization. The nature of the metal is important for activity and selectivity. Main-group organometallic compounds derived from Zn are of high synthetic utility since their carbon-metal bonds have essentially covalent character and are compatible with most functional groups encountered in sterically hindered amide bases such as 2,2,6,6-tetramethylpiperide bases (TMP)nMXm.pLiCl, LiCl. A selection of hindered metal amides for the metalation includes highly chemoselective magnesiation or zincation agents TMPMgCl·LiCl and TMP2Zn·2MgLiCl·2MgCl·2LiCl [25]. Lithium bases such as TMPLi are more powerful than magnesium and zinc equivalents. The bulky bases are constructed for high solubility in organic solvents. When desired, the initially metalated organic species may be transmetalated by another metal agent to modify reactivity characteristics. Several cases of oxidative metalations are illustrated in this review [25,26].
The hydrocarbon-soluble magnesium amide TMP2Mg (TMP = 2,2,6,6-tetramethylpiperidyl) shows excellent properties for the regioselective magnesiation of five-membered heterocycles such as imidazoles, benzoxazoles, benzofurane, and benzothiophene derivatives [27]. Imidazole and indole can be regarded as 1,3-dideaza and 1,3,7-trideaza purine. Related metalation chemistry in the five-membered ring is likely (Scheme 22). Subsequent trans-metalation using ZnCl2 in hydrocarbon-mixed solvents such as toluene and hexanes, affords the corresponding zincated organometallic intermediate useful for Pd-catalyzed trans-coupling reactions.
Purine nucleobases are good ligands for metal ions forming coordinative bonds. The N-donor atoms of the nucleobase skeleton become units in metal complexes (Scheme 23). C8-Bromo-C9-methyladenine 78 reacts with Pt(PPh3)4 under oxidative addition of the C8-halogen bond to the metal center to form a platinum complex 79 [28]. Protonation of the ylidene 79 at the N7/9-atom yields complexes bearing a protic N-heterocyclic carbene ligand 80 derived from the purine base. The N-7-position of N9-blocked species is the preferred binding site for transition metal ions, including Pt(II)-antitumor agents. Oxidative additions for C8-metalation of purine nucleobases are illustrated further for palladium complexes (Scheme 23) [29]. Modified RNA and DNA building blocks react readily with the Pd(PPh3)4 complex by oxidative addition of the C8-Br bond to give neutral azolate complexes 82. The azolato ligands in the complexes can be protonated at the annular N7-nitrogen atom to give complexes derived from nucleosides (83). The metal complexes bearing C8-metalated nucleoside are chiral and easily prepared. They are structurally stable. The authors suggest applications in asymmetric catalysis.

4. Halogenation

π-Deficient heteroaryl chemistry has been greatly involved in ring-forming reactions and the exchange of annular substituents, often by nucleophilic displacements of halides. In other cases, substituents are converted into groups with good leaving properties for subsequent substitution displacements, especially for reactions associated with bromides and chlorides. Iodides were less readily available but are presently also accessible via organometallic intermediates (vide infra). Fluorides in electrophilic sites are highly labile. Bromides and chlorides are prepared by direct electrophilic substitution or by halogen interchange reactions.

4.1. Chlorination

Various electrophilic or nucleophilic methodologies are available for the introduction of a chlorine atom at the C8-position in purine systems. In Scheme 24, the emphasis is on the recent versatile methodology developed by way of organometallic intermediates followed by electrophilic chlorination [30]. N9-THP-protected C6-chloropurine 84 is metalated by excess TMPLi in THF at −75 °C. Chlorination with C2Cl6 provides 2,4,6-trichloropurine 85 in 60% yield. The same 2,4,6-trichloride 85 is available by a slightly modified procedure. The N9-THP-protected 2,4-dichloropurine (86) is metalated at C8 on treatment with LDA in THF at −78 °C. Treatment of the lithium complex with hexachloroethane affords trichloride 85 in 54% yield.

4.2. Bromination

Simple electrophilic C8-bromination readily takes place in the C8-position. In Scheme 25, adenosine 3′,5′-cyclic monophosphate (cAMP) (87) is a substrate for the preparation of the C8-bromide 49 [1].
Bromination via organometallic intermediates offers a highly versatile approach for halogenation, at least for smaller-scale reactions (Scheme 26). Selective oxidative deprotonation at the C8-position using either zinc- or magnesium-amide bases such as TMP generates C8-metalated species 89 [3]. Electrophilic bromination by 1,2-dibromo-1,1,2,2.tetrachoroethane under Barbier conditions at 0 °C affords the C8-bromide 90 in high yield.

4.3. Iodination

Halogen exchange reactions can be used for the introduction of iodine into the C8-position [22,25]. C8-Iodo-derivatives are less readily available than their bromo and chloro analogues. Iodination can, however, be effected in reactions between molecular iodine and organometallic complexes. Iodination at C8 is achieved by conversion of 91a to the C6-chloro-C8-iodide 93a (Scheme 26) [22,25]. Selective deprotonation at C8 using either zinc- or magnesium-amide bases generates C8-metalated species as depicted by structure 92. Purines 91 are zincated using TMPZnCl·LiCl within 30 min at 25 °C. Subsequent trapping with iodine (1.2 equiv) provides corresponding iodinated compounds in 60–98% yields. The metalation with the organomagnesium base TMPMgCl·LiCl is run at −60 °C. Purine derivatives can be metalated at positions C8 and C6 using sterically shielded TMP-bases to produce magnesiation, zincation, or lithiation. The deprotonated species are nucleophilic reactants readily attacked by electrophiles. In Scheme 27, methoxymethyl (MOM)-protected purines 91 are zincated to organometallic species 92 using TMPZnCl·LiCl. Subsequent trapping with iodine provides the corresponding iodides 93 in 60–98% yield. The organomagnesium reagent TMPMgCl·LiCl, at −60 °C, furnishes the corresponding metal species in a similar yield. Trapping of the metalated species 95 with iodine provides the corresponding iodinated compounds 96 in 60–90% yield. A silyl group in the 2-position is not affected under the conditions used for metalation and direct iodination.

4.4. Fluorination

A fluorine atom attached to a π-electron deficient annular carbon is sensitive to nucleophilic displacement. Exposure of the fully O-protected C8-bromopurine 97 to cesium fluoride in acetonitrile at 100 °C for 12 h leads to halogen exchange with the formation of the C8-fluoride 98. (Scheme 28) [31]. The acetal protecting function in the fluoride is readily cleaved by 1% TFA whereas the acetonide function remains unchanged (99). Removal of the acetonide function from the fluoro derivative 99 is achieved by 10% aq. perchloric acid to afford the unmasked C8-fluoroadenosine 100. The C8-fluoro atom is strongly electronegative and has the capacity to attenuate the basicity of the nitrogen atom at the N7-position.
The use of elemental fluorine is an alternative to a halogen exchange reaction. Direct regioselective fluorination by elemental fluorine on unprotected purine nucleosides 101 delivers the C8-fluoride 102 (Scheme 29) [32,33]. The reaction is effected by bubbling elemental fluorine (1%) in helium into a solution of the unprotected or acetyl masked nucleoside in CHCl3. The acetyl masked fluoride (102b) is obtained in close to 30% yield. The unmasked substrate 101a affords 102a in 7% yield.
In a second series of reactions, peracetylated masked guanosine and adenosine are treated with elemental fluorine in CHCl3, MeCN, or MeNO2 to afford peracetylated C8-fluoroguanosine and C8-fluoroadenosine fluorides 104 and 107 together with the corresponding chlorides 105 and 108 in ratios 6:1 (Scheme 30) [34]. CHCl3 is the preferred solvent. Deprotection of the products is by ammonia in MeOH or 2-propanol. Additional ester cleavage in methanolic HCl delivers the unmasked products.
2′-Deoxyribonucleoside can be synthesized via metalation and subsequent fluorination under heterogeneous conditions with solid N-fluorobenzenesulfonimide (NFSi) as the fluorinating agent (Scheme 31) [35]. Prior to fluorination, di-TBDMS protected 2′-deoxyadenosine is metalated by LDA or nBuLi in toluene and THF at −78 °C. Solid NFSi is added to the cold reaction mixture for fluorination. The product is a mixture of the C8-fluoride 109 and the corresponding N6-phenylsulfonyl compound 110. This finding may suggest competing ionic and radical processes. Ribonucleosides give similar results. Silyl deprotection of the products is effected by tris(dimethylamino)sulfonium difluorotrimethylsilicate (TASF) in methylene chloride to afford C8-fluoro-2′deoxyribonucleosides.

5. Aza-, Oxa-, and Thia-Carbylations

5.1. Amines and Oxidized Forms

Simple C8-amino derivatives are available by displacement reactions between a C8-halide and an amine reactant. The transformation is illustrated by the reaction of hydroxylamine with C8-bromoguanosine (8) at elevated temperatures in methanol to afford the C8-hydroxylaminoguanosine 111 (Scheme 32) [36]. 8-Azido derivatives are readily formed by nucleophilic substitution reactions as in the preparation of the azide 112 from the C8-Br amidate 50 [37]. Azides are useful as intermediate substrates for subsequent conversions into amines or heterocycles and have been investigated for a variety of biological interactions. Stereoselective thiation of the azido-amidate 112 at the phosphorus atom and deprotection by ammonium fluoride afford the (Rp)-8-azide 113.
Azolation in the C8-position in the purine scaffold of cAMP and cAMPS provides derivatives with annular sp2-hybridized azolo-amino-nitrogen attached directly to the purine C8-position (Scheme 33) [37]. A solution of the (Sp)-C8-bromo amidate 50 and the sodium salts of the azoles in DMF afford C8-azolo products. Substitution of intermediate amidates with imidazole as a sodium salt in DMF proceeds readily at elevated temperatures to afford an imidazo derivative 114. 1,2,4-Triazoles afford the unsymmetrical N1-product 115 and triazaoles attached to the C8-position in the nucleotide. The metalated 1,2,4- triazole yields the 1,2,4 aminated product 116. 1,2,3-Triazole produces a mixture of the 2-triazolo isomer 116 and the 1-triazolo isomer 117 in the ratio 3:2. The triazolo heterocycles are π-electron deficient, and both the 1,2,3-triazoles and 1,2,4-triazoles possess low basicity. In contrast, imidazole behaves as a base and nucleophile.
Oxidative aminations via selective metalations are useful. Selective magnesiation in the C8-position by the reaction of purines 118 with TMPMgCl·LiCl under mild reaction conditions affords the transmetalated C8-cuprated purine lithium amide 119 (Scheme 34). Subsequent treatment with chloranil (−78 °C, 2 h) affords oxidative amination and formation of the C8-aminopurine 120 [38]. Oxidative amination using chloranil and N-lithium morpholide with the copper reagent affords the C8-morholino purine 123 from the C6-chloro substrate 121.
Metabolic activation of polycyclic aromatic hydrocarbons and arylamines causes DNA mutations that may ultimately lead to cancer. Synthetic methodology has been developed for the preparation of C8-arylamino nucleobases for the investigation of mutagenic properties. Scheme 35 illustrates syntheses of adenosine test compounds by cross-coupling procedures for the introduction of heteroatom substituents using anilines for aminations [39]. The C8-anilino product 124 is formed by cross-coupling between the bromoadenosine (1) and the aniline amino-nitrogen atom. The Pd-catalyzed reactions are promoted by racemic BINAP. A closer study of the reaction with aniline showed comparable activities for the (R)- and (S)-isomers and their racemate.

5.2. Nitro Functionalized Derivatives

A nitro group has been inserted into the C8-position in guanosine by a nucleophilic displacement reaction from the bromide 125 (Scheme 36) [40]. The (Rp)-C8-bromo-cGMPS (125) substrate is incubated with sodium nitrite in DMSO. The product is formed in a moderate yield. It is a chemically labile molecule due to nitro group displacements. Biologically, it acts as an endogenous potent inhibitor of protein kinase G1a that regulates physiological functions such as vascular smooth muscle relaxation, neural synaptic plasticity, and platelet activities. C8-Nitro-GMP causes persistent activations of PKG1a through covalent attachment of cGMP moieties to cysteine residues in the enzyme (protein guanylation). The rate constants for (Rp)-C8-nitro-cGMPS and C8-nitro-cGMP substitution reactions with low molecular-weight thiols in a neutral aqueous buffer are similar, suggesting closely related electrophilicity at the C8-carbon. (Sp)-GMPS binds to PKG1a and acts as an agonist in the test. (Rp)-C8-Nitro-cGMPS (126) reacts with the thiol function in cysteine and glutathione to form (Rp)-C8-thioalkoxy-cGMPS (127) analogues by thiol-affected nucleophilic replacement of the nitro group. This explains the permanent inhibition of PKG by (Rp)-C8-nitro-cGMPS (126). The attachment of the (Rp)-cGMPS moiety to the enzyme results in an induction of an S-guanylation-like modification.

5.3. C8-Sulfenyl Derivatives

C8-substituents with good leaving group properties are in general replaced readily by sulfur nucleophiles to afford C8-sulfenyl analogues or the parent C8-thiol. Subsequent oxidations provide sulfinyl and sulfonyl products.
Oxidative thiation offers an alternative approach by way of an organometallic intermediate (Scheme 37). Regioselective deprotonation at C8 in N9-benzyl-protected purine 128 by sterically hindered zinc-amide base generates a zincated species 129. The carbanionic intermediate 129 will cleave disulfides and afford sulfides [25]. The S-phenyl benzenesulfonothioate in Scheme 37 may be regarded as an activated disulfide reactant and readily undergoes a Barbier reaction at 0 °C to provide the C8-phenylthiopurine 130.

5.4. C8-Hydroxy Derivatives

Since cAMP is known to augment glucose-induced insulin secretion, structural analogues have been prepared and made available for biological investigations [41]. C8-Alkoxy analogues and C8-hydroxides are prepared by simple nucleophilic substitutions from C8-halopurines. The methyl ether 132 is generated from the C8-bromide (Sp)-131 and sodium methoxide (Scheme 38). The benzyl ether 132b is synthesized in a similar manner from benzyl alcohol. Benzyl ethers and analogues are potential substrates for corresponding hydroxyl compounds by catalytic hydrogenolysis.

6. Conclusions

Several methodologies are available for the introduction or exchange of substituents in the peripheral C8-position in the purine skeleton and its glycosidic derivatives. Metalations, organometallic intermediates, and cross-coupling reactions provide bond-forming carbylations. Alkyl, unsaturated alkyl, aryl, and heteroaryl substituents are inserted into the imidazo C8-postion. The same, or closely related intermediates, yield amines, sulfides, hydroxyl compounds, and ethers. Most chemical transformations involve organometallic species at some stage. Chemoselective, regioselective, and functionally selective metalations are essential. Electrophilic reactants add to the anionic metal-carbon intermediates for C-C or C-X bond formation to provide the product. The structural transformations selected and discussed deal with the imidazo part of the purine scaffold.

Funding

This research received no external funding.

Conflicts of Interest

The author declares no conflicts of interest.

References

  1. Andrei, M.; Bjørnstad, V.; Langli, G.; Rømming, C.; Klaveness, J.; Taskén, K.; Undheim, K. Stereoselective preparation of (Rp)-8-hetaryl-3′,5′-cyclic phosphorothioic acids. Org. Biomol. Chem. 2007, 54, 2070–2080. [Google Scholar] [CrossRef] [PubMed]
  2. Yates, M.K.; Seley-Rathke, K.L. The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Paert II: Complex modifications to the nucleoside scaffold. Antivir. Res. 2019, 162, 5–21. [Google Scholar] [CrossRef] [PubMed]
  3. Haag, B.; Mosrin, M.; Ila, H.; Malakhov, V.; Knochel, P. Regio- and Chemoselective Metalation of Arenes and Heteroarenes Using Hindered Metal Amide Bases. Angew. Chem. Int. Ed. 2011, 50, 9794–9824. [Google Scholar] [CrossRef] [PubMed]
  4. Undheim, K. Hetarylzinc Cross-Coupling Reactions, Science of Synthesis; Molander, G.A., Ed.; Georg Thieme Verlag KG: Stuttgart, Germany; New York, NY, USA, 2013; pp. 717–761. [Google Scholar]
  5. Hayakawa, H.; Haraguchi, K.; Tanaka, H.; Miyasaki, T. Direct C-8 Lithiation of Naturally-Occurring Purine Nucleosides. A Simple method for the Synthesis of 8-Carbon-Substituted Purine Nucleosides. Chem. Pharm. Bull. 1987, 35, 723–779. [Google Scholar] [CrossRef]
  6. Van Aerschot, A.A.; Mamos, P.; Weyns, N.J.; Ikeda, S.; De Clercq, E.; Herdewijn, P.A. Antiviral Activity of C-Alkylated Purine Nucleosides Obtained by Cross-Coupling with Tetraalkyltin Reagents. J. Med. Chem. 1993, 36, 2938–2942. [Google Scholar] [CrossRef] [PubMed]
  7. Hirota, K.; Kitade, Y.; Kanbe, Y.; Maski, Y. Convenient Method for the Synthesis of C-Alkylated Purine Nucleosides: Palladium Catalyzed Cross-Coupling Reactions of Halogenopurine Nucleosides with Trialkylaluminums. J. Org. Chem. 1992, 57, 5268–5270. [Google Scholar] [CrossRef]
  8. Manfredini, S.; Baraldi, P.G.; Bazzanini, R.; Marangoni, M.; Simoni, D.; Balzarini, J.; De Clercq, E. Synthesis and Cytotoxic Activiyty of 6-Vinyl and 6-Ethynyluridine and 8-Vinyl- and 8-Ethynyladenosine. J. Med. Chem. 1995, 38, 199–203. [Google Scholar] [CrossRef] [PubMed]
  9. Lang, P.; Gerez, C.; Tritsch, D.; Fontecave, M.; Biellmann, J.-F.; Burger, A. Synthesis of 8-vinyladenosine 5′-di- and 5′-triphosphate: Evaluation of the diphosphate compound on ribonucleotide reductase. Tetrahedron 2003, 59, 7315–7322. [Google Scholar] [CrossRef]
  10. Firth, A.C.; Fairlamb, I.J.S.; Darley, K.; Bauman, C.G. Sonogashira alkynylation of unprotected 8-brominated adenosines and guanosines: Fluorescence properties of compact conjugated acetylenes containing a purine ring. Tetrahedron Lett. 2006, 47, 3529–3533. [Google Scholar] [CrossRef]
  11. Ibrahim, N.; Chevot, F.; Legraverend, M. Regioselective Sonogashira cross-coupling reactions of 6-chloro-2,8-diiodo-9-THP-9H-purine with alkyne derivatives. Tetrahedron Lett. 2011, 52, 305–307. [Google Scholar] [CrossRef]
  12. Sági, G.; Ötvös, L.; Ikeda, S.; Andrei, G.; Snoeck, R.; De Clerq, E. Synthesis and Antiviral Activities of 8-Alkynyl-, 8-Alkenyl-, and 8- Alkyl-2′-deoxyadenosine Analogues. J. Med. Chem. 1994, 37, 1307–1311. [Google Scholar] [CrossRef] [PubMed]
  13. Volpini, R.; Costanci, S.; Lambertucci, C.; Vittori, S.; Klotz, K.-N.; Lorenzen, A.; Cristalli, G. Introduction of Alkynyl Chains on C-8 of Adenosine Led to Very selective Antagonists of the A3 Adenosine Receptor. Bioorg. Med. Chem. Lett. 2001, 11, 1931–1934. [Google Scholar] [CrossRef] [PubMed]
  14. Storr, T.E.; Baumann, C.G.; Thatcher, R.J.; De Ornellas, S.; Whitwood, A.C.; Fairlamb, I.J.S. Pd(0)/Cu(I)-Mediated Direct Arylation of 2′-Deoxyadenosines: Mechanistic Role of Cu(I) and Reactivity Comparisons with Related Purine Nucleosides. J. Org. Chem. 2009, 74, 5810–5821. [Google Scholar] [CrossRef] [PubMed]
  15. Collier, A.; Wagner, G. A facile two-step synthesis of 8-arylated guanosine mono- and triphosphates (8-aryl GXPs). Org. Biomol Chem. 2006, 4, 4526–4532. [Google Scholar] [CrossRef] [PubMed]
  16. Collier, A.; Wagner, G.R. Suzuki-Miyaura Cross-Coupling of Unprotected Halopurine Nucleosides in Water-Influence of Catalyst and Cosolvent. Synth. Commun. 2006, 36, 3713–3721. [Google Scholar] [CrossRef]
  17. Western, E.C.; Daft, J.R.; Johnson, E.M.; Gannett, P.M.; Shoughnessay, K.H. Efficient One-Step Suzuki Arylation of Unprotected Halonucleosides, Using Water-Soluble Palladium Calalysts. J. Org. Chem. 2003, 68, 6767–6774. [Google Scholar] [CrossRef] [PubMed]
  18. Zilberstein, L.; Silberman, A.; Fischer, B. 8-(p-CF3-cinnamyl)-modified purine nucleosides as promising fluorescent probes. Org. Biomol. Chem. 2011, 9, 7763–7773. [Google Scholar] [CrossRef] [PubMed]
  19. Undheim, K. cAMPS derivatives. A minireview over synthetic medicinal chemistry. Bioorg. Chem. 2019, 91, 103152. [Google Scholar] [CrossRef] [PubMed]
  20. Vongsutilers, V.; Daft, J.R.; Shaughnessy, K.H.; Gannett, P.M. A General Synthesis of C8-Arylpurine Phosphoramidites. Molecules 2009, 14, 3339–3352. [Google Scholar] [CrossRef] [PubMed]
  21. Akula, H.K.; Bae, S.; Pradhan, P.; Yang, L.; Zajc, B.; Lakshman, M.K. Diversely C8-functionalized adenine nucleosides via their underexplored carboxaldeshydes. Chem. Commun. 2022, 58, 1744–1747. [Google Scholar] [CrossRef]
  22. Zimdars, S.; du Jourdin, X.M.; Crestey, F.; Carell, T.; Knochel, P. Trifunctionalization of the Purine Scaffold Using Mg and Zn Organometallic Intermediates. Org. Lett. 2011, 13, 792–795. [Google Scholar] [CrossRef] [PubMed]
  23. Undheim, K.; Taskén, K.; Klaveness, J.; Langli, G.; Bjørnstad, V. Purine Nucleotide Derivatives. WO 2005/123755 29 December 2005. [Google Scholar]
  24. Gundersen, L.L. Synthesis of purinecarbonitriles by Pd(0)-catalyzed coupling of halopurines with Zinc cyanide. Acta Chem. Scand. 1996, 50, 58–63. [Google Scholar] [CrossRef]
  25. Crestey, F.; Zimdars, S.; Knochel, P. Regioselective Functionalization of Purine Derivatives at Position 8 and 6 Using Hindered TMP-Amide Bases of Zn and Mg. Synthesis 2013, 45, 3029–3037. [Google Scholar] [CrossRef]
  26. Dagousset, G.; Francois, C.; León, T.; Blanc, R.; Sansiaume-Dagousset, E.; Knochel, P. Preparation of Functionalized Lithium, Magnesium, Aluminum, Zinc, Manganese, and Indium Organometallics from Functionalized Organic Halides. Synthesis 2014, 46, 3133–3171. [Google Scholar] [CrossRef]
  27. Hess, A.; Alandini, N.; Guelen, H.C.; Prohaska, J.P.; Knochel, P. Regioselective magnesiations of functioalized arenes and hetarenes using TMP 2 Mg in hydrocarbons. Chem. Commun. 2022, 58, 8774–8777. [Google Scholar] [CrossRef] [PubMed]
  28. Brackemeyer, D.; Hervé, A.; Schulte, C.; Brinke, M.; Jahnke, M.C.; Hahn, F.E. A Versatile Methodology for the Regioselective C8-Metalation of Purine Bases. J. Am. Chem. Soc. 2014, 136, 7841–7844. [Google Scholar] [CrossRef] [PubMed]
  29. Kampert, F.; Brackemeyer, D.; Tan, T.T.; Hahn, F.E. Selective C8-Metalation of Purine Nucleosides via Oxidative Addition. Organometallics 2018, 37, 4181. [Google Scholar] [CrossRef]
  30. Hocek, M.; Havelkova, M.; Dvorak, D. The Suzuki-Miyaura Cross-Coupling Reactions of 2-, 6- or 8-Halopurines with Boronic Acids Leading to 2-, 6-, or 8-Aryl- and –Alkenylpurine Derivatives. Synthesis 2004, 11, 2869–2876. [Google Scholar] [CrossRef]
  31. Butora, G.; Schmitt, C.; Levorse, D.A.; Streckfuss, E.; Doss, G.A.; MacCoss, M. The elusive 8-fluoroadenosine: A simple non-enzymatic synthesis and characterization.Regioselective Fluorination. Tetrahedron 2007, 63, 3782–3789. [Google Scholar] [CrossRef]
  32. Barrio, M.; Namavari, M.; Phelps, M.E.; Saytyamurthy, N. Regioselective Fluorination on treating Guanines with Dilute F2: A Facile Entrance to 8-Fluoroguanine Derivatives. J. Org. Chem. 1996, 61, 6084–86085. [Google Scholar] [CrossRef] [PubMed]
  33. Barrio, J.R.; Namavari, M.; Phelps, M.E.; Satyamurthy, N. Elemental Fluorine to 8-Fluoropurines in One Step. J. Am. Chem. Soc. 1996, 118, 10408–10411. [Google Scholar] [CrossRef]
  34. Liu, J.; Barrio, J.R.; Satyamurthy, N. Kinetics and mechanism of the defluorination of 8-fluoropurine nucleosides in basic and acidic media. J. Fluorine Chem. 2006, 127, 1175–1187. [Google Scholar] [CrossRef]
  35. Ghosh, A.K.; Lagisetty, P.; Zajc, B. Direct Synthesis of 8-Fluoro Purine Nucleosides via Metalation-Fluorination. J. Org. Chem. 2007, 72, 8222–8226. [Google Scholar] [CrossRef] [PubMed]
  36. Long, R.A.; Robins, R.V.; Townsend, L.B. Purine Nucleosides. XV. The Synthesis of 8-Amino- and 8-Substituted Aminopurine Nucleosides. J. Org. Chem. 1967, 32, 2751–2756. [Google Scholar] [CrossRef] [PubMed]
  37. Andrei, M.; Undheim, K. Azolo substitution into the purine scaffold in nucleoside cyclic 3′,5′-phosphorothioates. Monatshefte Fürchemie Chem. Mon. 2022, 153, 1213–1223. [Google Scholar] [CrossRef]
  38. Boudet, N.; Dubbaka, S.; Knochel, P. Oxidative Amination of Cuprated Pyrimidine and Purine Derivatives. Org. Lett. 2008, 10, 1715–1718. [Google Scholar] [CrossRef] [PubMed]
  39. Schoffers, E.; Olsen, P.D.; Means, J.C. Synthesis of C8-Adenosine Adducts of Arylamines Using Palladium Catalysis. Org. Lett. 2001, 3, 4221–4223. [Google Scholar] [CrossRef] [PubMed]
  40. Ahmed, K.A.; Zhang, T.; Ono, K.; Tsutsuki, H.; Ida, S.; Akashi, S.Z.; Miyata, K.; Oike, Y.; Akaike, T.; Sawa, T. Synthesis and Characterization of 8-Nitroguanosine 3′,5′-Cyclic Monophosphorothioate Rp-Isomer as a Potent Inhibitor of Protein Kinase G1a. Biol. Pharm. Bull. 2017, 40, 365–374. [Google Scholar] [CrossRef] [PubMed]
  41. Schwede, F.; Bertinetti, D.; Langerijs, C.N.; Hadders, M.A.; Wienk, H.; Ellenbroek, J.H.; de Koning, E.J.P.; Bos, J.L.; Herberg, F.W.; Genieser, H.-G.; et al. Structure-Guided Design of Selected Epac1 and Epac2 Agonists. PLoS Biol. 2015, 13, 100203. [Google Scholar] [CrossRef] [PubMed]
Scheme 1. Reactions and conditions: (i) THF, LDA, MeI, 2 h, −70 °C; (ii) TBAF, THF, rt, 14 h.
Scheme 1. Reactions and conditions: (i) THF, LDA, MeI, 2 h, −70 °C; (ii) TBAF, THF, rt, 14 h.
Molecules 29 01815 sch001
Scheme 2. Reactions and conditions: (i) HMDS, reflux, 8 h (ii) R14Sn, Pd(PPh3)4, NMP, 130 °C, 20 h; (iii) NH4Cl, MeOH, rt, 18 h.
Scheme 2. Reactions and conditions: (i) HMDS, reflux, 8 h (ii) R14Sn, Pd(PPh3)4, NMP, 130 °C, 20 h; (iii) NH4Cl, MeOH, rt, 18 h.
Molecules 29 01815 sch002
Scheme 3. Reaction and conditions: (i) HMDS, cat NH4HSO4, reflux, 2–3 h; (ii) AlR13, (PPh3)2PdCl2, THF; (iii) MeOH, reflux, 3 h.
Scheme 3. Reaction and conditions: (i) HMDS, cat NH4HSO4, reflux, 2–3 h; (ii) AlR13, (PPh3)2PdCl2, THF; (iii) MeOH, reflux, 3 h.
Molecules 29 01815 sch003
Scheme 4. Reactions and conditions: Reactions and conditions: (i) Bu3SnCH=CH2, Pd(PPh3)4, DMF, THF, (ii) NH4F, MeOH, 70 °C.
Scheme 4. Reactions and conditions: Reactions and conditions: (i) Bu3SnCH=CH2, Pd(PPh3)4, DMF, THF, (ii) NH4F, MeOH, 70 °C.
Molecules 29 01815 sch004
Scheme 5. Reaction and conditions: (i) (a) Pd(PPh3)4, Bu3SnCH=CH2, DMF, 90 °C, (b) Bu4NF; (ii) TFA; (iii) (a) Bu4NF, (b) Ac2O; (iv) TFA, H2O; (v) (a) NBu3, pyridine, (b) Im2CO, DMF, (c) (HNBu3H)H2PO4 or (HNBu3)H2PO7, (d) NH3-MeOH, H2O, (e) Na+ exchange.
Scheme 5. Reaction and conditions: (i) (a) Pd(PPh3)4, Bu3SnCH=CH2, DMF, 90 °C, (b) Bu4NF; (ii) TFA; (iii) (a) Bu4NF, (b) Ac2O; (iv) TFA, H2O; (v) (a) NBu3, pyridine, (b) Im2CO, DMF, (c) (HNBu3H)H2PO4 or (HNBu3)H2PO7, (d) NH3-MeOH, H2O, (e) Na+ exchange.
Molecules 29 01815 sch005
Scheme 6. Reagents and conditions: (i) (PPh3)2PdCl2 (1 mol%), CuI (2 mol%), terminal acetylene, DMF, 110 °C, 18 h; (ii) MeOH, NH4F, 70 °C.
Scheme 6. Reagents and conditions: (i) (PPh3)2PdCl2 (1 mol%), CuI (2 mol%), terminal acetylene, DMF, 110 °C, 18 h; (ii) MeOH, NH4F, 70 °C.
Molecules 29 01815 sch006
Scheme 7. Reactions and conditions: (i) (PPh3)2PdCl2, CuI, NEt3, DMF, rt, 2–6 h; (ii) (a) (PPh3)2PdCl2., NEt3, DMF, 70 °C, 2–6 h; (b) NH3, MeOH. (iii) H2-Lind cat., MeOH, quinoline (2%), 1 atm., rt, 1–14 h.
Scheme 7. Reactions and conditions: (i) (PPh3)2PdCl2, CuI, NEt3, DMF, rt, 2–6 h; (ii) (a) (PPh3)2PdCl2., NEt3, DMF, 70 °C, 2–6 h; (b) NH3, MeOH. (iii) H2-Lind cat., MeOH, quinoline (2%), 1 atm., rt, 1–14 h.
Molecules 29 01815 sch007
Scheme 8. Reactions and conditions: (i) LiTMP, THF, −78 °C, 2 h; (ii) halides by I2 or 1,3.dibromo-3,5-dimethyl-hydantoin and carbylation; (iii) alkyne, CuI (12 mol%, Pd(PPh3)4 6 mol%), CsCO3, DMF, 2–3 h.
Scheme 8. Reactions and conditions: (i) LiTMP, THF, −78 °C, 2 h; (ii) halides by I2 or 1,3.dibromo-3,5-dimethyl-hydantoin and carbylation; (iii) alkyne, CuI (12 mol%, Pd(PPh3)4 6 mol%), CsCO3, DMF, 2–3 h.
Molecules 29 01815 sch008
Scheme 9. Reaction and conditions: (i) (PPh)2PdCl2, CuI, NEt3, DMF, 20 °C, 2–6 h; (ii) 5% NH3, aq. MeOH; (iii) H2/Lindlar; quinoline, MeOH, 20 °C, 2,5 h: (iv) H2, Pd/C (10%), EtOH, 1 atm, 1–14 h.
Scheme 9. Reaction and conditions: (i) (PPh)2PdCl2, CuI, NEt3, DMF, 20 °C, 2–6 h; (ii) 5% NH3, aq. MeOH; (iii) H2/Lindlar; quinoline, MeOH, 20 °C, 2,5 h: (iv) H2, Pd/C (10%), EtOH, 1 atm, 1–14 h.
Molecules 29 01815 sch009
Scheme 10. Reactions and conditions: (i) (PPh3)PdCl2, CuI, NEt3, rt; (ii) (PPh3)PdCl2, CuI, NEt3, rt.
Scheme 10. Reactions and conditions: (i) (PPh3)PdCl2, CuI, NEt3, rt; (ii) (PPh3)PdCl2, CuI, NEt3, rt.
Molecules 29 01815 sch010
Scheme 11. Reaction and conditions: (i) Pd(OAc)2 (5 mol%), CuI (3 equiv), ArI, Cs2CO3, piperidine, DMF, 80 °C, 15 h.
Scheme 11. Reaction and conditions: (i) Pd(OAc)2 (5 mol%), CuI (3 equiv), ArI, Cs2CO3, piperidine, DMF, 80 °C, 15 h.
Molecules 29 01815 sch011
Scheme 12. Reaction and conditions: (i) Na2C14Pd, p-R1-PhB(OH)2, TPPTS, K2CO3, 80 °C, 0.5–6 h.
Scheme 12. Reaction and conditions: (i) Na2C14Pd, p-R1-PhB(OH)2, TPPTS, K2CO3, 80 °C, 0.5–6 h.
Molecules 29 01815 sch012
Scheme 13. Reaction and conditions: (i) Pd(OAc)2, TPPTS, Na2CO3, MeCN:H2O (1:2), 80 °C, 2 h.
Scheme 13. Reaction and conditions: (i) Pd(OAc)2, TPPTS, Na2CO3, MeCN:H2O (1:2), 80 °C, 2 h.
Molecules 29 01815 sch013
Scheme 14. Reactions and conditions: (i) Suzuki trans-coupling; (ii) Sonogashira trans-coupling.
Scheme 14. Reactions and conditions: (i) Suzuki trans-coupling; (ii) Sonogashira trans-coupling.
Molecules 29 01815 sch014
Scheme 15. Reagents and conditions (i) (COCl)2, DMF, CH2Cl2, −20 °C, 1 h, (b) BnNH2, CH2Cl2, −60 °C-rt, 2.5 h; (ii) Pd(OAc)2, PPh3, NMP, (C6H4-4-F)SnBu3, 130 °C, 3–8 h; (iii) (a) BuLi, THF, rt, 1 h, (b) CS2; (iv) (a) NH4F, rt, 5 d, (b) NBu3.
Scheme 15. Reagents and conditions (i) (COCl)2, DMF, CH2Cl2, −20 °C, 1 h, (b) BnNH2, CH2Cl2, −60 °C-rt, 2.5 h; (ii) Pd(OAc)2, PPh3, NMP, (C6H4-4-F)SnBu3, 130 °C, 3–8 h; (iii) (a) BuLi, THF, rt, 1 h, (b) CS2; (iv) (a) NH4F, rt, 5 d, (b) NBu3.
Molecules 29 01815 sch015
Scheme 16. Reagents and conditions: (i) Pd(OAc)2, PPh3, R1SnBu3, solvent, 125–135 °C, 7–19 h; (ii) (a) tBuOK, THF, rt, 1 h, (b) CS2, 40 °C, 3 h, (iii) NH4F, DMF, rt, 3 d.
Scheme 16. Reagents and conditions: (i) Pd(OAc)2, PPh3, R1SnBu3, solvent, 125–135 °C, 7–19 h; (ii) (a) tBuOK, THF, rt, 1 h, (b) CS2, 40 °C, 3 h, (iii) NH4F, DMF, rt, 3 d.
Molecules 29 01815 sch016
Scheme 17. Reaction and conditions: (i) (4-R1C6H4B(OH)2, Pd(OAc)2, TPPTS, Na2CO3, MeOH; (ii) Me2NCH(OMe)2, MeOH.
Scheme 17. Reaction and conditions: (i) (4-R1C6H4B(OH)2, Pd(OAc)2, TPPTS, Na2CO3, MeOH; (ii) Me2NCH(OMe)2, MeOH.
Molecules 29 01815 sch017
Scheme 18. Reactions and conditions: (i) LDA, THF, −78 °C, HCO2Me; (ii) LDA, −78 °C, DMF, 2.5 h.
Scheme 18. Reactions and conditions: (i) LDA, THF, −78 °C, HCO2Me; (ii) LDA, −78 °C, DMF, 2.5 h.
Molecules 29 01815 sch018
Scheme 19. Reactions and conditions: (i) TMPZnCl·LiCl, (1.2 equiv), THF, 25 °C, 15 min: (ii) Pd(PPh3)4, MeOH, 45 °C, 30 min.
Scheme 19. Reactions and conditions: (i) TMPZnCl·LiCl, (1.2 equiv), THF, 25 °C, 15 min: (ii) Pd(PPh3)4, MeOH, 45 °C, 30 min.
Molecules 29 01815 sch019
Scheme 20. Reactions and conditions: (i) EtOCH=CH2, TFP, Pd2dba3·CHCl3, DMF, 80 °C, 17 h; (ii) K2CO3, MeOH, rt, 24 h; (iii) 1 M HCl, THF, rt, 20 h; (iv) NaBH4, THF, MeOH.
Scheme 20. Reactions and conditions: (i) EtOCH=CH2, TFP, Pd2dba3·CHCl3, DMF, 80 °C, 17 h; (ii) K2CO3, MeOH, rt, 24 h; (iii) 1 M HCl, THF, rt, 20 h; (iv) NaBH4, THF, MeOH.
Molecules 29 01815 sch020
Scheme 21. Reaction and conditions: (i) Pd2dba3·CHCl3, DPPF, Zn(CN)2, NMP, 120 °C; (ii) TBAF, THF, 0 °C, 4 h.
Scheme 21. Reaction and conditions: (i) Pd2dba3·CHCl3, DPPF, Zn(CN)2, NMP, 120 °C; (ii) TBAF, THF, 0 °C, 4 h.
Molecules 29 01815 sch021
Scheme 22. Reactions and conditions: (i) TMP2Mg, toluene/hexanes, −40–−65 °C, 5 min, 4 h; (ii) ZnCl2, toluene/hexanes, 0 °C, 0.5 h; (iii) ArI, Pd-cat, toluene/hexanes, THF, 55 °C, 16 h.
Scheme 22. Reactions and conditions: (i) TMP2Mg, toluene/hexanes, −40–−65 °C, 5 min, 4 h; (ii) ZnCl2, toluene/hexanes, 0 °C, 0.5 h; (iii) ArI, Pd-cat, toluene/hexanes, THF, 55 °C, 16 h.
Molecules 29 01815 sch022
Scheme 23. Reagents and reaction conditions. (i) Pt(PPh3)4, toluene, reflux, 6 d; (ii) NH4BF4, toluene, reflux 12 h; (iii) Pd(PPh3)4, 12 h, THF, 80 °C; (iv) HBF4·Et2O, 12 h, 0 °C.
Scheme 23. Reagents and reaction conditions. (i) Pt(PPh3)4, toluene, reflux, 6 d; (ii) NH4BF4, toluene, reflux 12 h; (iii) Pd(PPh3)4, 12 h, THF, 80 °C; (iv) HBF4·Et2O, 12 h, 0 °C.
Molecules 29 01815 sch023
Scheme 24. Reaction and conditions: (i) LiTMP, THF, −78 °C, 2 h; (ii) C2Cl6; (iii) LDA, THF, −78 °C; (iv) C2Cl6.
Scheme 24. Reaction and conditions: (i) LiTMP, THF, −78 °C, 2 h; (ii) C2Cl6; (iii) LDA, THF, −78 °C; (iv) C2Cl6.
Molecules 29 01815 sch024
Scheme 25. Reagents and reaction conditions: (i) (a) Br2, NaOAc, H2O, rt, (b) NaHSO3, (c) NaHCO3.
Scheme 25. Reagents and reaction conditions: (i) (a) Br2, NaOAc, H2O, rt, (b) NaHSO3, (c) NaHCO3.
Molecules 29 01815 sch025
Scheme 26. Reaction and conditions: (i) TMPZnCl·LiCl, THF; (ii) (CCl2Br)2.
Scheme 26. Reaction and conditions: (i) TMPZnCl·LiCl, THF; (ii) (CCl2Br)2.
Molecules 29 01815 sch026
Scheme 27. Reaction and conditions: (i) TMPZnCl·LiCl, THF. 30 min. rt; (ii) I2, THF, 1 h, rt or TMPMgCl·LiCl metalation at −60 °C; (iii) TMPZnCl·LiCl, 25 °C, 30 min; (iv) I2.
Scheme 27. Reaction and conditions: (i) TMPZnCl·LiCl, THF. 30 min. rt; (ii) I2, THF, 1 h, rt or TMPMgCl·LiCl metalation at −60 °C; (iii) TMPZnCl·LiCl, 25 °C, 30 min; (iv) I2.
Molecules 29 01815 sch027
Scheme 28. Reaction and conditions: (i) CsF, MeCN, 100 °C, sealed tube, 18 h; (ii) 1% TFA, 45 min, (iii) 10% HClO4, 1 h.
Scheme 28. Reaction and conditions: (i) CsF, MeCN, 100 °C, sealed tube, 18 h; (ii) 1% TFA, 45 min, (iii) 10% HClO4, 1 h.
Molecules 29 01815 sch028
Scheme 29. Reaction and conditions. (i) Fluorine (1% in He 0.6 mmol) is bubbled into a solution of the unprotected purine derivative (0.3) mmol in absolute ethanol (6.0 mL) and tetramethylammonium hydroxide (0.34 mL) of 20% aq. solution at rt over a period of 1 h.
Scheme 29. Reaction and conditions. (i) Fluorine (1% in He 0.6 mmol) is bubbled into a solution of the unprotected purine derivative (0.3) mmol in absolute ethanol (6.0 mL) and tetramethylammonium hydroxide (0.34 mL) of 20% aq. solution at rt over a period of 1 h.
Molecules 29 01815 sch029
Scheme 30. Reaction and conditions. (i) Fluorine (1% in He or Arg), CHCl3, rt, 2–5 h.
Scheme 30. Reaction and conditions. (i) Fluorine (1% in He or Arg), CHCl3, rt, 2–5 h.
Molecules 29 01815 sch030
Scheme 31. Reaction and conditions: (i) (a) LDA), heptane/THF/toluene, −78 °C, 2 h, (b) NFSi (solid, 3 equiv.), −78 °C to 0 °C, 75 min.
Scheme 31. Reaction and conditions: (i) (a) LDA), heptane/THF/toluene, −78 °C, 2 h, (b) NFSi (solid, 3 equiv.), −78 °C to 0 °C, 75 min.
Molecules 29 01815 sch031
Scheme 32. Reagents and reaction conditions. (i) NH2OH, MeOH, 100 °C, 18 h; (ii) NaN3, DMF, 60 °C, 20 h. (iii) (a) LDA, THF/heptane/ethylbenzene, −78 °C, 10 min; (iv) CS2, rt, 10 min; (v) hexane; (vi) NH4F, MeOH, 45 °C, 4 h.
Scheme 32. Reagents and reaction conditions. (i) NH2OH, MeOH, 100 °C, 18 h; (ii) NaN3, DMF, 60 °C, 20 h. (iii) (a) LDA, THF/heptane/ethylbenzene, −78 °C, 10 min; (iv) CS2, rt, 10 min; (v) hexane; (vi) NH4F, MeOH, 45 °C, 4 h.
Molecules 29 01815 sch032
Scheme 33. Reagents and conditions. (i) (Sp)-50, imidazole, NaH, DMF, rt, 30 min, 80 °C, 4–20 h; or (ii) (Sp)-50, 1,2,4-triazole, DMF, 60 °C, 20 h (iii) (Sp)-50, 1,2,3-triazole, NaH, DMF, rt. 20 h.
Scheme 33. Reagents and conditions. (i) (Sp)-50, imidazole, NaH, DMF, rt, 30 min, 80 °C, 4–20 h; or (ii) (Sp)-50, 1,2,4-triazole, DMF, 60 °C, 20 h (iii) (Sp)-50, 1,2,3-triazole, NaH, DMF, rt. 20 h.
Molecules 29 01815 sch033
Scheme 34. Reaction and conditions: (i) TMPMgCl·LiCl, −10 °C, 2 h; (ii) CuCl2·2LiCl, NEt3, −50 °C, 1 h; (iii) LiNEt2; −60 °C, 1 h; (iv) chloranil, −80 °C to −50 °C, 12 h; (v) TMPMgCl·LiCl, THF. −10 °C, 2-3 h, (vi) CuCl·2LiCl, −60 °C, 1 h; (vii) N-lithium morpholide, −60 °C, 1 h; (viii) chloranil, −78 °C, 12 h.
Scheme 34. Reaction and conditions: (i) TMPMgCl·LiCl, −10 °C, 2 h; (ii) CuCl2·2LiCl, NEt3, −50 °C, 1 h; (iii) LiNEt2; −60 °C, 1 h; (iv) chloranil, −80 °C to −50 °C, 12 h; (v) TMPMgCl·LiCl, THF. −10 °C, 2-3 h, (vi) CuCl·2LiCl, −60 °C, 1 h; (vii) N-lithium morpholide, −60 °C, 1 h; (viii) chloranil, −78 °C, 12 h.
Molecules 29 01815 sch034
Scheme 35. Reaction and conditions: (i) ArNH2, Pd2(dba)3, BINAP, NaOtBu, toluene, 85–110 °C.
Scheme 35. Reaction and conditions: (i) ArNH2, Pd2(dba)3, BINAP, NaOtBu, toluene, 85–110 °C.
Molecules 29 01815 sch035
Scheme 36. Reagents and conditions: (i) NaNO2, DMSO, HCl, 70 °C, 3 d; (ii) cysteine, 8 equiv., borate buffer (100 mM, pH 12). 90 °C until complete reaction, HPLC.
Scheme 36. Reagents and conditions: (i) NaNO2, DMSO, HCl, 70 °C, 3 d; (ii) cysteine, 8 equiv., borate buffer (100 mM, pH 12). 90 °C until complete reaction, HPLC.
Molecules 29 01815 sch036
Scheme 37. Reagents and conditions: (i) TMP2Zn·2MgCl2·2LiCl, THF, 0–25 °C, 15 min; (ii) THF, 0 °C, 5 min.
Scheme 37. Reagents and conditions: (i) TMP2Zn·2MgCl2·2LiCl, THF, 0–25 °C, 15 min; (ii) THF, 0 °C, 5 min.
Molecules 29 01815 sch037
Scheme 38. Reagents and reactions: (i) MeONa, MeOH, DMSO, 70 °C; (ii) BnONa, BnOH, DMSO, 70 °C.
Scheme 38. Reagents and reactions: (i) MeONa, MeOH, DMSO, 70 °C; (ii) BnONa, BnOH, DMSO, 70 °C.
Molecules 29 01815 sch038
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Undheim, K. Bond Formation at C8 in the Nucleoside and Nucleotide Purine Scaffold: An Informative Selection. Molecules 2024, 29, 1815. https://doi.org/10.3390/molecules29081815

AMA Style

Undheim K. Bond Formation at C8 in the Nucleoside and Nucleotide Purine Scaffold: An Informative Selection. Molecules. 2024; 29(8):1815. https://doi.org/10.3390/molecules29081815

Chicago/Turabian Style

Undheim, Kjell. 2024. "Bond Formation at C8 in the Nucleoside and Nucleotide Purine Scaffold: An Informative Selection" Molecules 29, no. 8: 1815. https://doi.org/10.3390/molecules29081815

APA Style

Undheim, K. (2024). Bond Formation at C8 in the Nucleoside and Nucleotide Purine Scaffold: An Informative Selection. Molecules, 29(8), 1815. https://doi.org/10.3390/molecules29081815

Article Metrics

Back to TopTop